Second-line treatments refer to options beyond steroids and methotrexate. They are designed to manage JM while reducing reliance on those medications. We understand that adding new treatments to your child’s regimen can be intimidating. However, rest assured that your doctor has carefully considered the benefits and risks of each option to design the best treatment plan for your family.
The Cure JM Clinical Care Network hosted our second quarterly virtual symposium of 2024, “Juvenile Dermatomyositis – Advances in Clinical Care, Basic Research, and Translational Studies.” World-leading researchers and clinicians presented sessions on various topics, with the primary goal of enhancing the overall patient and provider experience through collaboration and best practice sharing.
Two special guest speakers, Michelle Vogel, MPA, IV Solutions RX, and Laurel Cherwin, BSN, RN, IgCN, Octapharma, shared information on navigating affordable treatments and care for JM patients.
Membership is free and we’ll connect you with a network of support, encouragement, and resources.
To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.
